departur confid inspir downgrad
messag recent announc departur ceo aron knickerbock
plan pursu new opportun mr knickerbock departur follow
cso bryan irv critic time compani life-cycle dont think
news inspir confid fprx platform pipelin earlier today read
modest activ mab esmo stock alreadi trade
cash downgrad neutral buy remov
price target
pipelin critic junctur manag departur dont inspir confid
pipelin gener upsid view recent announc chief
execut offic board member aron knickerbock resign compani
pursu new challeng opportun board initi search process recruit
perman ceo meanwhil mr ringo compani chairman sinc januari
serv interim ceo earlier year may dr bryan irv resign
posit compani chief scientif offic order pursu anoth opportun
lead program bemarituzumab head phase futil
analysi earli recal earlier year surprisingli ad futil analysi
trial greater-than-expect number enrol patient test posit
requir biomark howev major patient identifi via
rather ctdna test suggest receptor over-express absenc
gene amplif contrast compani expect
posit patient ctdna posit given discrep
compani incorpor futil analysi schedul earli unlik tradit
futil analys howev aim confirm studi drug harm
analysi also incorpor efficaci compon repres higher hurdl
potenti point possibl trial contain high rate biomark false-
posit patient view recal fight trial evalu bemarituzumab
front-lin gastric cancer patient partnership zlab
phase ib/ii asset antibodi readout esmo demonstr modest
efficaci patient expans dose recal link
report dose escal data all-com popul includ modest
orr among patient high express orr among low
medium expressor esmo present single-ag efficaci
phase ib dose expans portion includ respons among patient
breast endometri ovarian cancer data modest view especi
consid expans enrol high express patient
mg/kg expans dose furthermor major diseas progress patient death
occur within month patient remain treatment yet
exceed month time therapi data cutoff
previous guid read initi dose escal safeti data
anticip earli efficaci readout per
earn call compani dose escal cohort enrol time
visibl out-licens program august phase ii trial
antibodi cabiralizumab combin nivolumab pancreat cancer complet
enrol soon accord may enabl read data
antibodi cite increas phase trial size
patient current includ either program estim
page analyst certif import disclosur
remov pt prior pt end cash
page analyst certif import disclosur
valuat risk
valu use dcf base valuat valuat includ lead product
bemarituzumab well probability-adjust cash flow deriv compani pipelin
use discount rate consist commerci stage biotech compani
coverag termin growth rate appli termin year post-assum
downsid risk includ regulatori commerci setback potenti emerg
new competitor dilut financ beyond assum
upsid risk includ higher product sale expect pipelin success beyond
alreadi account forecast potenti acquisit due valuat innov
page analyst certif import disclosur
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
